Evommune
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1891 Page Mill Rd, Palo Alto, California...Phone Number
(925) 247-4481Website
www.evommune.comRevenue
$10 MillionStock Symbol
EVMNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
3
1
1
1
About Evommune
Evommune is a clinical stage biotechnology company focused on developing therapies that address the underlying drivers of chronic inflammatory diseases. The company uses advanced immunology research to create targeted treatments aimed at improving patient outcomes beyond symptom control, with a pipeline designed for conditions where current treatment options remain limited.Explore more
Evommune Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evommune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Evommune launches new products
Check out if Evommune is spiking on competitors!
Evommune, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Evommune recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Evommune has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Evommune has new funding data
Congratulate Masked Content for being promoted to Masked Content at Evommune
Click to see if Evommune had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Evommune
Find 2 more new buyers
Compare Similar Companies to Evommune
Compare insights from companies similar to Evommune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Evommune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Evommune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Evommune.
Evommune financials insights
Gather financial insights about Evommune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$12.5M
2023
Series B
$57.5M
2024
Series C
$115M
Evommune Tech Stack
A closer look at the technologies used by Evommune
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Evommune News & Media
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38%...Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention April 13, 2026 2:00 PM EDTCompany...Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PALO ALTO, Calif., Nov. 7, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the closing of its initial public offering of 10,781,250 shares of...NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading
NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on November...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evommune
Sign Up For FreeTo access detailed company insights
Evommune is a clinical stage biotechnology company focused on developing therapies that address the underlying drivers of chronic inflammatory diseases. The company uses advanced immunology research to create targeted treatments aimed at improving patient outcomes beyond symptom control, with a pipeline designed for conditions where current treatme... Read More
